MedTrace Logo

Study of Photobiomodulation to Treat Dry Age-Related Macular Degeneration (LIGHTSITE III)

NCT04065490 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 96

Last updated 2021-02-05

No results posted yet for this study

Summary

This LIGHTSITE III study is a double-masked, sham-controlled, parallel design, prospective multi-site study for the use of PBM as a treatment for visual impairment in subjects with dry AMD.

Conditions

Interventions

DEVICE

Valeda PBM treatment

The Valeda Light Delivery System

DEVICE

Valeda Sham treatment

The sham mode of the Valeda Light Delivery System.

Sponsors & Collaborators

  • LumiThera, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-09-01
Primary Completion
2022-06-01
Completion
2022-06-01
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04065490 on ClinicalTrials.gov